Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1998 Feb;168(2):133–139.

Practical issues regarding the use of antiretroviral therapy for HIV infection.

S G Deeks 1
PMCID: PMC1304849  PMID: 9499754

Abstract

With the recent development of potent new antiretroviral therapies, the management of HIV infection has become increasingly complex. There are now 12 antiretroviral drugs approved for use in the management of HIV infection, with several more in the advanced stages of clinical development. Staying current with this rapidly changing area of medicine is a challenge to clinicians caring for HIV-infected patients. This review provides an overview of HIV pathogenesis and discusses the basic principles of therapy. These principles, developed recently by the U.S. Department of Health and Human Services, provide a practical framework to rapidly incorporate new developments into clinical practice. Each of the three classes of antiretroviral therapies is then explained, focusing on the practical management of side effects, drug interactions, and viral resistance. The antiviral activity and clinical efficacy of each therapeutic class is reviewed, with an emphasis on applying current results to clinical decision making. Finally, recently published treatment guidelines are reviewed.

Full text

PDF
133

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet. 1997 Apr 12;349(9058):1086–1092. [PubMed] [Google Scholar]
  2. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Saag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997 Jun 25;277(24):1962–1969. [PubMed] [Google Scholar]
  3. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  4. Condra J. H., Holder D. J., Schleif W. A., Blahy O. M., Danovich R. M., Gabryelski L. J., Graham D. J., Laird D., Quintero J. C., Rhodes A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996 Dec;70(12):8270–8276. doi: 10.1128/jvi.70.12.8270-8276.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. D'Aquila R. T., Hughes M. D., Johnson V. A., Fischl M. A., Sommadossi J. P., Liou S. H., Timpone J., Myers M., Basgoz N., Niu M. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med. 1996 Jun 15;124(12):1019–1030. doi: 10.7326/0003-4819-124-12-199606150-00001. [DOI] [PubMed] [Google Scholar]
  6. Deeks S. G., Abrams D. I. Genotypic-resistance assays and antiretroviral therapy. Lancet. 1997 May 24;349(9064):1489–1490. doi: 10.1016/S0140-6736(05)62092-2. [DOI] [PubMed] [Google Scholar]
  7. Deeks S. G., Smith M., Holodniy M., Kahn J. O. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997 Jan 8;277(2):145–153. [PubMed] [Google Scholar]
  8. Hammer S. M., Katzenstein D. A., Hughes M. D., Gundacker H., Schooley R. T., Haubrich R. H., Henry W. K., Lederman M. M., Phair J. P., Niu M. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct 10;335(15):1081–1090. doi: 10.1056/NEJM199610103351501. [DOI] [PubMed] [Google Scholar]
  9. Kahn J. O., Lagakos S. W., Richman D. D., Cross A., Pettinelli C., Liou S. H., Brown M., Volberding P. A., Crumpacker C. S., Beall G. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992 Aug 27;327(9):581–587. doi: 10.1056/NEJM199208273270901. [DOI] [PubMed] [Google Scholar]
  10. Kopp J. B., Miller K. D., Mican J. A., Feuerstein I. M., Vaughan E., Baker C., Pannell L. K., Falloon J. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997 Jul 15;127(2):119–125. doi: 10.7326/0003-4819-127-2-199707150-00004. [DOI] [PubMed] [Google Scholar]
  11. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  12. Spruance S. L., Pavia A. T., Mellors J. W., Murphy R., Gathe J., Jr, Stool E., Jemsek J. G., Dellamonica P., Cross A., Dunkle L. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997 Mar 1;126(5):355–363. doi: 10.7326/0003-4819-126-5-199703010-00003. [DOI] [PubMed] [Google Scholar]
  13. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES